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ABSTRACT
Objective: To determine whether 4 genetic variants in the fat mass and obesity associated gene
(FTO) identified in genome-wide association studies of diabetes and obesity are associated with
cognitive change in midlife in the Atherosclerosis Risk in Communities (ARIC) Study.
Methods: ARIC is a prospective cohort study of the development of atherosclerosis in 15,792 individ-
uals aged 45 to 64 years at baseline from 1986 to 1989. FTO is highly expressed in human fetal and
adult brain, and a single nucleotide polymorphism in FTO has previously been associated with reduced
brain volume in cognitively normal subjects. Since a relationship between brain atrophy and diminished
cognitive function has been demonstrated in ARIC participants, general linear models were used to
evaluate the association between 6-year change in scores on 3 neuropsychological tests and FTO
genotype.
Results: In a sample of 8,364 white and 2,083 African American men and women with no clinical his-
tory of stroke, significantly greater mean change in performance on the DelayedWord Recall Test was
associated with 2 of 4 FTO single nucleotide polymorphisms examined (rs9939609, rs805136,
rs17817449, and rs1421085) in whites but not in African Americans (p # 0.002). The association
of theFTO polymorphismswith cognitive changewas independent of potential confounding clinical and
demographic variables including age, gender, education, diabetes, hypertension, and body mass index.
Conclusions: Further studies will be needed to clarify the biological mechanisms and genetic path-
ways throughwhich variants in FTO can increase susceptibility to decline in verbal memory detectable
in middle-aged, community-dwelling adults. Neurology 2013;80:92–99
GLOSSARY
ARIC 5 Atherosclerosis Risk in Communities; BMI 5 body mass index; CI 5 confidence interval; DSST 5 Digit Symbol
Substitution Test; DWRT 5 Delayed Word Recall Test; SNP 5 single nucleotide polymorphism; WFT 5 Word Fluency Test;
WHR 5 waist-to-hip ratio.
Genetic variants in the fat mass and obesity associated gene (FTO), located on human chromosome
16q12.2, have been reproducibly associated with body mass index (BMI)1–3 and diabetes1,4,5 in
genome-wide association studies in children and adults of European descent, with variable repli-
cation in other ethnicities.6 FTO is ubiquitously expressed in human tissues including the fetal
and adult brain with high levels found in the hypothalamus, cerebellar cortex, temporal lobe,
and parietal lobe.1,2 The minor alleles of 4 single nucleotide polymorphisms (SNPs) in FTO
(rs9939609, rs8050136, rs17817449, and rs1421085) were associated with risk of diabetes and
obesity in white participants in the Atherosclerosis Risk in Communities (ARIC) Study, whereas
only rs1421085 was a determinant of obesity susceptibility in African Americans and was mod-
erately protective against diabetes.7 In accordance with previous evidence that individuals who are
obese showed differences in brain structure compared with subjects whose weight was in the normal
range, significantly decreased brain volume in the frontal lobes and occipital lobes has recently been
reported for carriers of the FTO rs3751812 T allele in a study of 206 cognitively normal subjects
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assessed by MRI.8–10 Since brain atrophy has
previously been observed in individuals with
lower cognitive performance in a number of
population-based epidemiologic studies,11,12
the association between the same 4 SNPs span-
ning a 19.6-kb region within intron 1 and var-
iation in cognitive status and cognitive decline
was analyzed in a sample of 8,364 white and
2,083 African American participants in the
ARIC study.
METHODS ARIC study. The ARIC study is a prospective,
longitudinal, biracial investigation of the development of atherosclero-
sis and its clinical sequelae in which 15,792 individuals aged 45 to 64
years from 4 communities in the United States were enrolled at
baseline from 1986 to 1989. A detailed description of the ARIC study
has previously been reported.13 Four examinations have been per-
formed at 3-year intervals, and subjects are contacted annually to
update their medical histories between examinations. Individuals were
not included in this analysis if they were neither African American nor
white (n 5 48), were African Americans from the Minnesota or
Maryland field centers because of the small numbers of individuals
recruited from these sites (n5 55), restricted use of their DNA (n5
45), had a history of physician-diagnosed stroke before visit 2 (n 5
271), or did not attend the visit 2 clinical examination (n 5 1,431).
Additional exclusions were made for incident stroke verified by ARIC
clinicians from medical records through visit 4 (n 5104), missing
cognitive data for all 3 neuropsychological tests at either visit 2 or visit
4 (n 5 2,906), missing genotype data (n 5 461), or for missing
information concerning years of education completed (n 5 24).
Standard protocol approvals, registrations, and patient
consents. Written informed consent was provided by all study par-
ticipants, and the study design and methods were approved by insti-
tutional review boards at the collaborating medical centers.
Genotype determination. Genotyping of the FTO and APOE
polymorphisms using DNA isolated from peripheral blood lympho-
cytes was performed using the TaqMan system (Applied Biosystems,
Foster City, CA). Sequences for primers and probes are available upon
request. Allele detection was performed using the ABI Prism 7700
Sequence Detection System (Applied Biosystems). The genotype call
rate was determined before exclusion of individuals from the analysis
and was 94.2% for rs9939609, 94.4% for rs17817449, 94.2%
for rs8050136, and 94.3% for rs1421085. After the application of
all exclusion criteria, the proportion of missing genotype data in the
final study sample ranged from 1.4% for rs17817449 to 1.7% for
rs8050136. The genotyping success rate was also assessed by analyzing
the concordance between genotypes for pairs of blind duplicates
included with the DNA samples from the study participants. Kappa
coefficients,14 indices of the percent agreement betweenmeasurements
corrected for agreement occurring by chance, were calculated for each
SNP and were 0.97 for rs9939608 and 0.98 for rs17817449,
rs8050136, and rs1421085.
Cognitive tests. Cognitive function was assessed using 3 neuropsy-
chological tests at the second (1990–1992) and fourth (1996–1998)
clinical examinations: 1) the Delayed Word Recall Test (DWRT) is a
test of verbal learning and recent memory in which the participant is
required to use each of 10 common nouns in a sentence. After a 5-
minute delay in which another test is given, the participant is asked to
recall the 10 nouns. The DWRT score is the number of correct words
recalled (range 0–10). A 6-month test-retest reliability of 0.75 was
reported in 26 normal elderly adults15; 2) theDigit Symbol Substitution
Test (DSST) is a subtest of the Wechsler Adult Intelligence Scale–
Revised involving timed translation of numbers to symbols using a
key with paired symbols and digits.16 The test measures psychomotor
performance, and is relatively unaffected by intellectual ability, learning,
or memory.17 The total number of correct translations within 90 sec-
onds determines the score (range 0–93). The correlation coefficient for
test-retest reliability over 2 to 5 weeks is 0.82 in 45- to 54-year-old
adults16; and 3) the Word Fluency Test (WFT) is a measure of exec-
utive function. In 3 separate 1-minute trials, the subject is asked to
generate as many words as possible beginning with the letters F, A, and
S.17 The score is the combined total of correct words produced. Test-
retest reliability is 0.74 for up to 5 years in older adults.18 The tests were
administered by trained interviewers in a standardized order and were
given in a single session. The examination sessions were monitored by
tape recorder and a sample of sessions was evaluated to confirm that
there were no systematic differences in mean test scores obtained by
different interviewers. Six-year change in cognitive function was
Table 1 FTO genotype and allele frequencies in the ARIC study
FTO SNP
African American White
No. % HWE (p) No. % HWE (p)
rs9939609
TT 581 28.8 0.36 2,920 35.3 0.08
AT 966 47.9 4,006 48.5





CC 678 33.3 0.31 2,899 35.2 0.34
AC 985 48.3 3,993 48.5





TT 780 38.8 0.31 2,913 35.1 0.19
GT 921 45.9 4,018 48.5





TT 1,618 79.6 0.40 2,832 34.3 0.45
CT 395 19.4 4,026 48.8




Abbreviations: ARIC 5 Atherosclerosis Risk in Communities; HWE 5 Hardy-Weinberg equi-
librium; rs 5 reference SNP; SNP 5 single nucleotide polymorphism.
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analyzed as the difference between the test score obtained at the later of
the 2 clinic visits and the test score obtained at the earlier examination
for each neuropsychological test.
Clinical and laboratory measurements. The clinical and lab-
oratory measurements used for this study were assessed during the
second clinical examination (visit 2, 1990–1992) with the exception
of education, which was evaluated at the baseline examination (visit 1,
1987–1989). Highest level of education attained (#11 years; 12–16
years;.17 years) was included as a covariate in regressionmodels and
coded as an additive categorical variable. Plasma total cholesterol and
triglycerides were measured by enzymatic methods, and low-density
lipoprotein cholesterol was calculated.19–21 High-density lipoprotein
cholesterol was measured after dextran-magnesium precipitation of
non–high-density lipoprotein cholesterol.22 Hypercholesterolemia
was defined as low-density lipoprotein cholesterol $130 mg/dL
(3.36 mmol/L).23 Blood pressure was measured 3 times while seated
using a random-zero sphygmomanometer and the last 2 measure-
ments were averaged for analysis. Hypertension was defined by
diastolic blood pressure of $90 mm Hg, systolic blood pressure
of $140 mm Hg, or use of antihypertensive medication. Fasting
serum glucose was measured using a standard hexokinase method on
a Coulter DACOS chemistry analyzer (Coulter Instruments, Fuller-
ton, CA). The prevalence of diabetes was defined using a fasting
glucose level.126 mg/dL (6.99 mmol/L), a nonfasting glucose level
.200 mg/dL (11.10 mmol/L), and/or self-reported physician diag-
nosis or treatment for diabetes. Body weight and other anthropometric
variables were measured by trained technicians according to standard-
ized protocols. BMI was calculated as weight in kilograms/(height in
meters)2. Waist-to-hip ratio (WHR) was calculated as waist girth in
centimeters/hip girth in centimeters. Information on cigarette smok-
ing and alcohol use was obtained using an interviewer-administered
questionnaire and status was classified as current, former, or never.
Statistical analysis. All statistical analyses were performed using
Stata 9 software (StataCorp, College Station, TX). Hardy-Weinberg
equilibrium was tested using a x2 goodness-of-fit test for all individ-
uals in each racial group. The proportions, means, and standard
deviations were calculated for cardiovascular risk factors for individ-
uals categorized by FTO genotype. Comparisons were performed
using x2 tests for categorical variables and t tests for continuous
variables. General linear models were used to assess mean differences
in cognitive change among groups of individuals categorized by FTO
genotype assuming an additive genetic model and adjusting for age,
gender, and educational level. Tests of interaction were conducted by
including main effects for each FTO polymorphism and measure-
ments of body size in the general linear models, and introducing a
multiplicative 2-way interaction term for gene by anthropometric
measurement. Multivariable logistic regression was used to estimate
the risk of being in the top decile of score change compared with
being in the other 9 deciles combined for each of the cognitive tests.
Linkage disequilibriumwas estimated usingHaploview version 4.2.24
The Bonferroni correction was used to adjust for multiple compar-
isons; a p value,0.002 was considered statistically significant for all
tests (a level 5 0.05/4 FTO variants 3 change in scores for 3
neurocognitive tests 3 2 racial groups). The results of the statistical
analyses are reported separately by self-reported racial group.
RESULTS The allele and genotype frequencies for 4
FTO SNPs were in accordance with Hardy-Weinberg
expectation for whites and African Americans and
did not vary by decade of life (all p . 0.15) (table 1).
All of the FTO polymorphisms were highly correlated
in whites (r2 . 0.94) whereas there was weaker
linkage disequilibrium between the SNPs in African
Americans (table e-1 on the Neurology® Web site at
www.neurology.org). A description of the study sample
at baseline stratified by race, or race and FTO genotype,
is displayed in tables 2 and 3, respectively. For white
participants, mean BMI and WHR varied by
rs9939609 genotype, with similar results found for
rs17817449, rs8050136, and rs1421085. For African
Americans, a significant difference in mean BMI with
genotype was seen only for rs1421085 (p 5 0.03) as
was previously reported.7 When cognitive status as as-
sessed by scores on 3 neuropsychological tests was ana-
lyzed at baseline, there was no significant difference in
mean test scores by FTO genotype for either white or
African American ARIC study participants (table 3).
In the primary analyses of the association of cognitive
change and FTO sequence variation adjusted for age,
gender, and years of education, there was a significant
Table 2 Clinical and demographic characteristics of theARIC study (1990–1992)
White (n 5 8,364)
African American
(n 5 2,083)
No. No. (%) No. No. (%) p
Male 8,364 3,859 (46.1) 2,083 716 (34.4) ,0.001
Education, y 8,364 2,083
£11 1,185 (14.2) 684 (32.8) ,0.001
>11 to £16 3,841 (45.9) 618 (29.7)
>16 3,338 (39.9) 781 (37.5)
Current smokers 8,362 1,572 (18.8) 2,075 459 (22.1) 0.001
Current alcohol use 8,362 5,473 (65.4) 2,077 709 (34.1) ,0.001
Hypertension 8,344 2,304 (27.6) 2,068 1,042 (50.4) ,0.001
Diabetes 8,354 864 (10.3) 2,056 423 (20.6) ,0.001
Obese (BMI ‡30 kg/m2) 8,359 2,019 (24.2) 2,081 899 (43.2) ,0.001
Hypercholesterolemia 8,212 4,132 (50.3) 2,046 1,067 (52.2) 0.138
APOE e4 8,101 2,218 (27.4) 1,853 757 (40.8) ,0.001
Mean (SD) Mean (SD)
Age, y 8,364 57.0 (5.6) 2,083 55.8 (5.7) ,0.001
Dbp, mm Hg 8,363 71.1 (9.7) 2,083 74.9 (10.2) ,0.001
Sbp, mm Hg 8,363 119.0 (17.1) 2,083 124.4 (18.8) ,0.001
Glucose, mmol/L 8,360 6.0 (1.7) 2,069 6.8 (2.9) ,0.001
BMI, kg/m2 8,359 27.3 (4.9) 2,081 30.0 (6.0) ,0.001
Total cholesterol,
mmol/L
8,353 5.4 (1.0) 2,062 5.4 (1.0) 0.247
LDL cholesterol,
mmol/L
8,212 3.4 (0.9) 2,046 3.5 (1.0) 0.018
HDL cholesterol,
mmol/L
8,328 1.3 (0.4) 2,055 1.4 (0.4) ,0.001
Triglycerides,
mmol/L
8,351 1.6 (0.9) 2,062 1.2 (0.7) ,0.001
Abbreviations: APOE e4 5 carriage of at least 1 apolipoprotein E e4 allele; ARIC 5 Ather-
osclerosis Risk in Communities; BMI 5 body mass index; Dbp 5 diastolic blood pressure;
HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein; Sbp 5 systolic blood pressure.
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difference found in whites for mean 6-year change in
DWRT scores between individuals classified on the basis
of genotype for 2 of the FTO SNPs (rs8050136 and
rs1421085, p # 0.002) using general linear models for
analysis of covariance (tables 4 and 5). However, no sig-
nificant variation among FTO genotypes was observed
for mean 6-year change in DWRT scores for African
American study participants, and there was no association
between FTO genotype and 6-year change in scores
detected for the DSST or the WFT for either racial
group. When change in cognitive function over a 6-year
period was analyzed further by adjusting for potential
confounding variables including diabetes case status,
hyperten-sion case status, cigarette smoking, hypercholes-
terolemia, APOE e4 carrier status, and BMI (table 5),25
the association between cognitive change as measured by
scores on the DWRT and FTO genotype appeared to be
independent of the risk factors examined for white study
participants. When interaction terms were included in
the models, there was no evidence for gene by BMI or
gene by WHR interaction for any of the FTO sequence
variants (all p . 0.3). Similarly, mean change in test
scores for the DWRT was significantly associated
with all 2-, 3-, and 4-locus haplotypes in whites but
not with any of the FTO marker combinations in
African Americans (table e-1). In an exploratory
Table 3 Baseline cognitive test scores and anthropometric measurements stratified by FTO genotype and race
Race/test





pMean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
White
DWRT 6.8 (1.4) 6.8 (1.4) 6.9 (1.4) 0.17 6.8 (1.4) 6.8 (1.4) 6.9 (1.4) 0.16
DSST 49.5 (11.2) 49.9 (11.2) 49.9 (11.3) 0.12 49.5 (11.2) 49.9 (11.2) 49.9 (11.4) 0.20
WFT 35.1 (11.6) 35.4 (11.9) 35.2 (11.8) 0.51 35.1 (11.5) 35.4 (11.8) 35.2 (11.8) 0.53
BMI (kg/m2) 27.0 (4.6) 27.4 (5.0) 27.7 (5.0) ,0.001a 27.0 (4.6) 27.4 (5.0) 27.7 (5.0) ,0.001a
WHR (cm/cm) 0.92 (0.08) 0.92 (0.08) 0.93 (0.08) ,0.001a 0.92 (0.08) 0.92 (0.08) 0.93 (0.08) ,0.001a
African American
DWRT 6.3 (1.5) 6.3 (1.6) 6.4 (1.6) 0.96 6.3 (1.6) 6.3 (1.6) 6.4 (1.6) 0.82
DSST 33.6 (13.1) 32.6 (13.1) 33.8 (13.0) 0.84 33.1 (13.2) 32.7 (13.0) 34.3 (13.2) 0.38
WFT 30.2 (12.5) 29.4 (13.2) 29.4 (12.8) 0.26 29.6 (12.4) 29.5 (13.2) 29.2 (13.1) 0.67
BMI (kg/m2) 29.7 (6.2) 30.1 (6.1) 30.0 (5.8) 0.35a 29.7 (6.2) 30.1 (5.9) 30.1 (5.9) 0.10a






pMean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
White
DWRT 6.8 (1.4) 6.8 (1.4) 6.9 (1.4) 0.11 6.8 (1.4) 6.8 (1.4) 6.9 (1.4) 0.14
DSST 49.4 (11.1) 49.9 (11.2) 49.9 (11.4) 0.11 49.5 (11.2) 49.9 (11.2) 49.9 (11.3) 0.14
WFT 35.1 (11.5) 35.4 (11.9) 35.2 (11.7) 0.52 35.0 (11.5) 35.4 (11.8) 35.5 (11.8) 0.18
BMI (kg/m2) 27.0 (4.6) 27.4 (5.0) 27.8 (5.0) ,0.001a 26.9 (4.6) 27.4 (5.0) 27.7 (5.0) ,0.001a
WHR (cm/cm) 0.92 (0.08) 0.92 (0.08) 0.93 (0.08) ,0.001a 0.92 (0.08) 0.92 (0.08) 0.93 (0.08) ,0.001a
African American
DWRT 6.3 (1.5) 6.3 (1.6) 6.3 (1.6) 0.97 6.4 (1.6) 6.2 (1.6) 6.3 (1.4) 0.16
DSST 33.0 (13.3) 32.9 (13.1) 34.1 (13.2) 0.31 33.2 (13.2) 32.8 (13.0) 33.6 (11.9) 0.72
WFT 29.6 (12.5) 29.7 (13.3) 29.2 (12.7) 0.70 29.7 (12.9) 29.2 (13.1) 26.2 (9.2) 0.30
BMI (kg/m2) 29.9 (6.2) 30.0 (6.0) 30.0 (5.7) 0.54a 29.9 (6.0) 30.2 (6.2) 32.5 (7.3) 0.03a
WHR (cm/cm) 0.91 (0.07) 0.92 (0.07) 0.92 (0.07) 0.67a 0.92 (0.07) 0.92 (0.07) 0.93 (0.07) 0.12a
Abbreviations: BMI 5 body mass index; DSST 5 Digit Symbol Substitution Test; DWRT 5 Delayed Word Recall Test; p 5 unadjusted p value; WFT 5 Word
Fluency Test; WHR 5 waist-to-hip ratio.
a The p value was adjusted for age and gender.
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analysis, the association between measures of brain
volume and FTO genotype was evaluated in a subset
of participants who underwent a cerebral MRI exam-
ination in 2004–2006, but no significant relationship
was observed (table e-2).
An association between FTO genotype and cognitive
change was also examined using logistic regression to
predict the risk of being in the decile of change score
showing the greatest decline for each of the 3 neuropsy-
chological tests rather than in the other 9 deciles com-
bined. An increased susceptibility to cognitive decline
associated with each addition of an FTO minor allele
was seen only in white ARIC study participants for
6-year change in scores on the DWRT. For these indi-
viduals, the odds ratios for greatest decline after adjust-
ment for age, gender, and education were 1.10 (95%
confidence interval [CI]5 1.01–1.19, p5 0.03) for the
addition of the rs8050136 A allele, 1.09 (95% CI 1.00–
1.18, p 5 0.05) for the rs17817449 G allele, and 1.11
(95% CI5 1.02–1.21, p5 0.01) for the rs1421085 C
allele, but there was no significant association observed
for the rs9939609 A allele (odds ratio 5 1.08, 95%
CI 5 1.00–1.18, p 5 0.06).
DISCUSSION Genome-wide association studies of BMI
have identified possible causal variants in genes that are
either highly expressed in the brain, or have known func-
tions in the CNS, such as FTO, melanocortin 4 receptor
(MC4R), proopiomelanocortin (POMC), SH2 adaptor
protein 1 (SH2B1), and brain-derived neurotrophic factor
(BDNF), that are implicated in the regulation of energy
balance and body weight.26,27 For example, mice deficient
in Fto show postnatal growth retardation, loss of white
adipose tissue, and increased energy expenditure,28 and
deletion of Bdnf in the hypothalamus results in hyperpha-
gia and increased adiposity.29 Rare mutations in both
POMC and MC4R cause severe monogenic forms of
obesity.30 BDNF is also involved in memory formation
and synaptic plasticity,31 and the results of the study re-
ported here suggest that 2 sequence variants in FTO that
are associated with susceptibility to obesity and diabetes
may have a second independent role in cognitive aging.
The FTO rs3751812 variant associated with deficits
in brain volume in the Alzheimer’s Disease Neuroimag-
ing Initiative8 is in strong linkage disequilibrium (r2 .
0.90) with all 4 of the SNPs genotyped in the ARIC
cohort in Utah residents with ancestry from northern






pMean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
White
DWRT 20.09 (1.52) 20.10 (1.48) 20.24 (1.51) 0.009 20.08 (1.52) 20.11 (1.48) 20.23 (1.51) 0.006
DSST 22.63 (6.74) 22.74 (6.12) 22.79 (6.26) 0.39 22.61 (6.67) 22.76 (6.17) 22.74 (6.48) 0.45
WFT 20.27 (7.89) 20.52 (7.92) 20.31 (7.86) 0.62 20.26 (7.86) 20.50 (7.91) 20.29 (7.86) 0.64
African
American
DWRT 20.32 (1.69) 20.23 (1.73) 20.21 (1.68) 0.30 20.31 (1.74) 20.23 (1.69) 20.13 (1.70) 0.10
DSST 21.75 (8.52) 21.69 (8.74) 22.70 (8.52) 0.10 21.97 (8.49) 21.56 (8.85) 22.97 (8.15) 0.28





pMean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
White
DWRT 20.08 (1.52) 20.11 (1.48) 20.24 (1.51) 0.004 20.07 (1.51) 20.12 (1.47) 20.23 (1.54) 0.002
DSST 22.60 (6.71) 22.77 (6.13) 22.76 (6.51) 0.35 22.59 (6.72) 22.77 (6.16) 22.78 (6.45) 0.27
WFT 20.28 (7.87) 20.54 (7.91) 20.29 (7.84) 0.66 20.26 (7.82) 20.47 (7.94) 20.44 (7.90) 0.36
African
American
DWRT 20.30 (1.70) 20.25 (1.74) 20.14 (1.67) 0.17 20.27 (1.73) 20.14 (1.65) 20.29 (1.55) 0.22
DSST 21.84 (8.34) 21.72 (8.96) 22.54 (8.27) 0.30 21.86 (8.73) 22.12 (8.33) 22.48 (6.11) 0.55
WFT 20.67 (7.93) 21.10 (8.39) 20.95 (8.33) 0.49 20.90 (8.21) 21.23 (8.38) 1.76 (6.53) 0.99
Abbreviations: ARIC 5 Atherosclerosis Risk in Communities; DSST 5 Digit Symbol Substitution Test; DWRT 5 Delayed
Word Recall Test; p 5 unadjusted p value; WFT 5 Word Fluency Test.
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and western Europe (CEPH), and with rs1421085
in populations of African ancestry (r2 5 1.00 in Yoruba
in Ibadan, Nigeria [YRI]; r2 5 1.00 in African ancestry
in southwest United States [ASW]) included in the
International HapMap project.32 However, there
were no significant alterations associated with the FTO
rs3751812 genotype after the regression models were
adjusted for age, sex, and BMI so that the brain atrophy
observed in the Alzheimer’s Disease Neuroimaging
Initiative may have been mediated by BMI, while
Table 5 Mean change in cognitive function and FTO genotype: ARIC study (1990–1992 and 1996–1998)
rs9939609 rs8050136 rs17817449 rs1421085
Neurocognitive test (white) b SE p b SE p b SE p b SE p
DWRT
Model 1 (FTO genotype adjusted
for age, sex, education)
20.064 0.024 0.007 20.072 0.024 0.002 20.068 0.024 0.004 20.078 0.024 0.001
Model 2 (model 1 1 BMI, DM, HT,
smoking, CHOL)
20.062 0.024 0.011 20.069 0.024 0.004 20.065 0.024 0.007 20.076 0.024 0.001
Model 3 (model 1 1 BMI, DM, HT,
smoking, CHOL, APOE4)
20.063 0.025 0.011 20.071 0.025 0.004 20.066 0.024 0.007 20.078 0.024 0.002
DSST
Model 1 (FTO genotype adjusted
for age, sex, education)
20.093 0.101 0.356 20.105 0.102 0.300 20.086 0.101 0.397 20.126 0.101 0.215
Model 2 (model 1 1 BMI, DM, HT,
smoking, CHOL)
20.088 0.103 0.390 20.098 0.103 0.341 20.080 0.103 0.435 20.114 0.103 0.269
Model 3 (model 1 1 BMI, DM, HT,
smoking, CHOL, APOE4)
20.102 0.103 0.324 20.106 0.104 0.308 20.097 0.104 0.352 20.118 0.104 0.256
WFT
Model 1 (FTO genotype adjusted
for age, sex, education)
20.066 0.126 0.602 20.061 0.126 0.628 20.065 0.125 0.606 20.121 0.125 0.333
Model 2 (model 1 1 BMI, DM, HT,
smoking, CHOL)
20.051 0.128 0.689 20.046 0.128 0.721 20.050 0.127 0.691 20.099 0.127 0.436
Model 3 (model 1 1 BMI, DM, HT,
smoking, CHOL, APOE4)
20.040 0.130 0.758 20.042 0.130 0.748 20.056 0.129 0.665 20.110 0.129 0.396
rs9939609 rs8050136 rs17817449 rs1421085
Neurocognitive test (African
American) b SE p b SE p b SE p b SE p
DWRT
Model 1 (FTO genotype adjusted
for age, sex, education)
0.057 0.053 0.277 0.076 0.054 0.161 0.094 0.055 0.088 0.110 0.087 0.210
Model 2 (model 1 1 BMI, DM, HT,
smoking, CHOL)
0.055 0.054 0.304 0.081 0.055 0.140 0.096 0.056 0.086 0.109 0.089 0.220
Model 3 (model 1 1 BMI, DM, HT,
smoking, CHOL, APOE4)
0.078 0.057 0.167 0.107 0.058 0.065 0.124 0.059 0.036 0.169 0.094 0.071
DSST
Model 1 (FTO genotype adjusted
for age, sex, education)
20.449 0.269 0.095 20.289 0.274 0.291 20.303 0.278 0.276 20.302 0.442 0.495
Model 2 (model 1 1 BMI, DM, HT,
smoking, CHOL)
20.390 0.274 0.154 20.242 0.279 0.387 20.282 0.283 0.320 20.442 0.452 0.328
Model 3 (model 1 1 BMI, DM, HT,
smoking, CHOL, APOE4)
20.433 0.291 0.137 20.313 0.298 0.293 20.406 0.301 0.178 20.585 0.481 0.224
WFT
Model 1 (FTO genotype adjusted
for age, sex, education)
20.216 0.253 0.394 20.141 0.259 0.587 20.098 0.262 0.708 0.015 0.419 0.972
Model 2 (model 1 1 BMI, DM, HT,
smoking, CHOL)
20.126 0.258 0.626 20.062 0.265 0.814 20.011 0.268 0.967 0.044 0.428 0.918
Model 3 (model 1 1 BMI, DM, HT,
smoking, CHOL, APOE4)
0.037 0.275 0.892 0.029 0.283 0.917 0.032 0.286 0.911 0.071 0.458 0.877
Abbreviations:APOE45 carriage of at least 1 apolipoprotein E e4 allele; ARIC5 Atherosclerosis Risk in Communities; b5 beta coefficient; BMI5 bodymass index;
CHOL5 low-density lipoprotein cholesterol$130 mg/dL defined based on the National Cholesterol Education Program (Adult Treatment Panel III); DM5 diabetes
mellitus (type 2); DSST5 Digit Symbol Substitution Test; DWRT5 Delayed Word Recall Test; HT5 hypertension; SE5 standard error; WFT5 Word Fluency Test.
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unexpectedly the effect of the 4 FTO variants on change
in memory was not attenuated by the inclusion of BMI
and diabetes.
In contrast to the known effects of chronic caloric
excess, which can include failure of insulin production
in combination with insulin resistance in metabolic tis-
sues, caloric restriction in which food intake is limited
without malnutrition results in lower blood glucose
and insulin, reduced energy stores in the form of gly-
cogen and fat, increased resistance to external stress,
and increased lifespan in laboratory rodents.33 In accor-
dance with a study demonstrating that a high-calorie
diet increases the risk of Alzheimer disease,34 caloric
restriction has been shown to prevent amyloid plaque
development in Tg2576 transgenic mice,35 providing
plausibility for biological pathways that may control
both energy metabolism and age-dependent mainte-
nance of neuronal integrity that affects cognitive status.
The impact of obesity on cognitive function, rather
than its genetic determinants, has also been examined
in several large epidemiologic studies in individuals with-
out dementia.36–39 To evaluate the relationship with mid-
life obesity, BMI and WHR were assessed in 1,814 men
and women aged 40 to 69 years in the Framingham
Offspring Cohort, and a WHR in the upper quartile at
baseline was associated with significantly lower perfor-
mance on tests of executive function and visuomotor
skills 12 years later.36 There was also a linear trend for
greater 5-year decline in scores for a test of delayed word
recall with increasing BMI in a cohort of healthy French
workers.37 In the Whitehall II Study of 9,181 white Brit-
ish civil service workers aged 35 to 55 years, long-term
obesity was associated with lower scores on the Mini-
Mental State Examination, a test of immediate memory,
and a composite measure of executive function that
included a test similar to the WFT.38 In contrast, higher
BMI did not predict cognitive decline in residents of
Chicago aged 65 years and older who were not impaired
at baseline.39 Differences in the ages of the study partic-
ipants, study design, the neuropsychological tests used to
assess cognitive function, as well as the indices of obesity
among the various studies, make it difficult to directly
compare these results with those found for the FTO
sequence variants; however, taken together, these reports
suggest that obesity is associated with performance inmul-
tiple cognitive domains whereas variation in FTO was
limited to decline in memory in the ARIC study. Simi-
larly, diabetes case status has been associated with signif-
icantly poorer cognitive performance in various cognitive
domains including global cognitive function, executive
function, immediate and delayed memory, visual atten-
tion, and processing speed in several longitudinal studies.40
When the association between the 4 FTO polymor-
phisms and susceptibility to diabetes was previously
investigated in the ARIC study, variation in the influ-
ence of the gene in whites and African Americans was
observed.7 In this study, there was no association between
any of the tests of cognitive function and the FTO
sequence variants in African Americans despite adequate
power to detect an effect of the same magnitude that was
found for whites (R2 # 0.01) (table e-3). This would be
consistent with the observed differences in linkage dise-
quilibrium between the polymorphisms in whites and
African Americans if there were a causative variant under-
lying the association that was located elsewhere in the
gene and was correlated with at least 2 of the SNPs in
whites but with none of the sequence variants in African
Americans. Alternatively, although the same criteria were
applied in both racial groups, 26.9% of whites and
50.4% of African Americans were excluded from analy-
sis, including a higher proportion of African Americans
than whites who were eligible for the study at baseline
but who died during the 6-year follow-up period (8.4%
and 5.4%, respectively; p# 0.001), so it is possible that
selection bias may have contributed to the lack of asso-
ciation found for African American subjects.
Although the amount of change in test scores ob-
served for white study participants was modest, replica-
tion of this finding in other populations is warranted to
confirm the role of FTO in decline in memory detect-
able in middle-aged adults.
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